Deletion of the key catalytic enzyme methylthioadenosine phosphorylase (MTAP) gene is associated with the sensitivity of GSK3368715,331 and a current phase II clinical study of GSK3368715 in breast cancer has been enrolled (NCT04676516) (Table 1). The gene discussed is MTAP; the disease is breast carcinoma.